A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh/AXLlow melanoma
暂无分享,去创建一个
K. Flaherty | J. Wargo | R. Marais | C. Wellbrock | Michael P. Smith | E. Rowling | J. Ferguson | S. Rana
[1] K. Flaherty,et al. Toward Minimal Residual Disease-Directed Therapy in Melanoma , 2018, Cell.
[2] R. Sturm,et al. BRN2, a POUerful driver of melanoma phenotype switching and metastasis , 2018, Pigment cell & melanoma research.
[3] T. Graeber,et al. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. , 2018, Cancer cell.
[4] Huadong Liu,et al. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma , 2018, Nature Communications.
[5] F. Al-Ejeh,et al. MITF and BRN2 contribute to metastatic growth after dissemination of melanoma , 2017, Scientific Reports.
[6] E. Rozeman,et al. Cancer Drug Addiction is Relayed by an ERK2-Dependent Phenotype Switch , 2017, Nature.
[7] D. Lipsker,et al. MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma , 2017, Clinical Cancer Research.
[8] Reinhard Dummer,et al. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure , 2017, EMBO molecular medicine.
[9] N. Haass,et al. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF , 2017, EBioMedicine.
[10] G. Firestone,et al. Inhibition of oncogenic BRAF activity by indole‐3‐carbinol disrupts microphthalmia‐associated transcription factor expression and arrests melanoma cell proliferation , 2017, Molecular carcinogenesis.
[11] C. Wellbrock,et al. The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer , 2016, Front. Cell Dev. Biol..
[12] Charles H. Yoon,et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.
[13] K. Flaherty,et al. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy , 2016, Cancer cell.
[14] C. Wellbrock,et al. Microphthalmia‐associated transcription factor in melanoma development and MAP‐kinase pathway targeted therapy , 2015, Pigment cell & melanoma research.
[15] S. Aerts,et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state , 2015, Nature Communications.
[16] T. Graeber,et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma , 2014, Nature Communications.
[17] J. Mesirov,et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. , 2014, Cancer discovery.
[18] Rajiv Narayan,et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition , 2013, Nature.
[19] Jun S. Song,et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition , 2013, Proceedings of the National Academy of Sciences.
[20] R. Marais,et al. Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma , 2012, Journal of the National Cancer Institute.
[21] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[22] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[23] G. Castellano,et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. , 2011, The Journal of investigative dermatology.
[24] M. Herlyn,et al. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway , 2011, Oncogene.
[25] E. Sahai,et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. , 2011, Cancer cell.
[26] D. Dembélé,et al. Genome‐wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene , 2010, Pigment cell & melanoma research.
[27] C. Fletcher,et al. The Role of MITF Phosphorylation Sites During Coat Color and Eye Development in Mice Analyzed by Bacterial Artificial Chromosome Transgene Rescue , 2009, Genetics.
[28] P. Nuciforo,et al. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. , 2008, Cancer research.
[29] Helen Pickersgill,et al. Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF , 2008, PloS one.
[30] G. Cavet,et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL , 2007, Nature Medicine.
[31] N. Hayward,et al. Confirmation of a BRAF mutation-associated gene expression signature in melanoma. , 2007, Pigment cell research.
[32] I. S. Dunn,et al. Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression , 2006, Molecular Cancer Research.
[33] D. Schadendorf,et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.
[34] R. Marais,et al. Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation , 2005, The Journal of cell biology.
[35] R. Sturm,et al. Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. , 2005, Experimental cell research.
[36] M. Herlyn,et al. Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. , 2003, The Journal of investigative dermatology.
[37] M. Schartl,et al. Activation of p59Fyn Leads to Melanocyte Dedifferentiation by Influencing MKP-1-regulated Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.
[38] M. Wegner,et al. Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. , 2000, Human molecular genetics.
[39] M. Schartl,et al. Activation of phosphatidylinositol 3-kinase by a complex of p59fyn and the receptor tyrosine kinase Xmrk is involved in malignant transformation of pigment cells. , 2000, European journal of biochemistry.
[40] E. Price,et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. , 2000, Genes & development.
[41] A. McKenna,et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.
[42] M. Schartl,et al. Activation of p 59 Fyn Leads to Melanocyte Dedifferentiation by Influencing MKP-1-regulated Mitogen-activated Protein Kinase Signaling * , 2002 .